Sanofi India Limited has informed the Exchange about appointment of Senior Management Personnel of the Company.
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanofi India's board, meeting on July 16, 2025, approved three key matters. First, Mr. Rachid Ayari, the current Chief Financial Officer, was appointed as Interim Managing Director for a 6-month term starting July 21, 2025, until a permanent MD is appointed, filling the gap left by Mr. Rodolfo Hrosz who stepped down on April 30, 2025. Second, Mr. Aniket Raje was appointed as Head of Regulatory Affairs effective August 1, 2025, bringing over 21 years of pharma experience, including a prior stint at Sanofi Healthcare India. Third, the company signed a 5-year exclusive distribution and promotion agreement with Emcure Pharmaceuticals for its oral anti-diabetic brands Amaryl and Cetapin, with Sanofi retaining manufacturing ownership. The deal is effective immediately, and no employees will transfer from Sanofi to Emcure.
The CFO taking interim MD charge signals leadership continuity at Sanofi India while it searches for a permanent head, which should reassure investors. The Emcure partnership leverages Emcure's wide India distribution network to drive volume growth for two established diabetes brands in a market where over 100 million Indians live with type 2 diabetes, potentially boosting future revenues. Investors should watch for the announcement of a permanent Managing Director in the coming months.